Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves Immunomedics' Breast Cancer Drug

By Taylor Carmichael – Apr 22, 2020 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Trodelvy is the first treatment approved specifically for triple-negative breast cancer.

On Wednesday the Food and Drug Administration granted accelerated approval to Immunomedics (IMMU) for its antibody drug conjugate treatment for triple-negative breast cancer (TNBC).  The treatment, which has the generic name sacituzumab govitecan, will be marketed by the company as Trodelvy. It's the first pharmaceutical to be approved for metastatic TNBC, and will be given to patients who have received two prior treatments for the disease. 

"We are proud to bring Trodelvy to patients with metastatic TNBC who are in dire need of new options. Trodelvy has the potential to become a standard of care in the management of TNBC, and we anxiously await the results of ongoing studies in other types of metastatic breast cancer," said Dr. Loretta M. Itri, the chief medical officer of Immunomedics. 

Trodelvy will carry a black box warning for severe neutropenia (a low count of a type of white blood cell) and severe diarrhea. The drug is expected to become a blockbuster. It is also being tested for other indications, including bladder and lung cancer. Seattle Genetics once offered a $2 billion deal to acquire the drug, and the initial agreement led to a proxy fight for control of Immunomedics.

Indeed, not one but two CEOs lost their job over the fate of Trodelvy. The founder of the company, Dr. David Goldenberg, and CEO Cynthia Sullivan, his wife, both left the company after the Seattle Genetics deal was scuttled and they lost a proxy fight with the company's top investor, hedge fund venBio. Then Sullivan's successor, Michael Pehl, lost his job last year after the FDA declined to approve Trodelvy because of manufacturing issues.

Immunomedics has put together a 130-person sales force to introduce the drug to physicians. Its stock has doubled over the last month.  

Taylor Carmichael owns shares of Immunomedics. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool recommends Immunomedics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunomedics, Inc. Stock Quote
Immunomedics, Inc.
IMMU

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.